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Abstract
Background: Pulmonary hypertension is a contradiction for heart transplantation (HTx). 
The aim of the study was to examine prognostic significance of pulmonary hemodynamic va-
riables in patients with severe chronic heart failure (HF) considered for HTx.
Methods: Patients with HF were qualified to HTx in Poland. We measured pulmonary 
artery systolic pressure (PASP), pulmonary capillary wedge pressure (PCWP), transpulmo-
nary gradient (TPG), cardiac output (CO), pulmonary vascular resistance (PVR) and syste-
mic vascular resistance (SVR). We performed biochemical evaluation, 6-min walking test,  
VO2max. Death or emergency HTx were assumed as the endpoints in the follow-up. Death 
or any kind of HTx were considered an end of observation. Survival analysis was conducted 
using Kaplan-Meier curves (long rank test with strait defined by terciles of analyzed hemody-
namic parameters).
Results: Six hundred and fifty-eight patients were qualified to HTx between 2003 and 2007. 
The mean follow-up: 601 days. 87.8% male. Mean age was under 50, III and IV NYHA class. 
Mean PASP was 44.3 ± 16.9 mm Hg, TPG 10.0 ± 6.6 mm Hg and PVR 2.9 mm Hg, PCWP 
20.9 ± 9.3 mm Hg. PASP and PCWP had influence on survival or emergency HTx. There was 
a significant difference in survival between patients with PCWP > 25 mm Hg and PCWP <  
< 25 mm Hg. The worst prognosis was with PASP higher than 50 mm Hg. One-, two-, and 
three-year survival was 75%, 58% and 48% compared to patients with PASP < 35 mm Hg 
(80%, 70%, and 68%, respectively).
Conclusions: In patients qualified to HTx, pathological values of pulmonary hemodynamic 
parameters have a significant influence on survival. The worst prognosis have patients with 
PASP > 50 mm Hg, and PCWP > 25 mm Hg. Pulmonary hemodynamic parameters are 
important during allocation process to HTx. (Cardiol J 2014; 21, 5: 532–538)
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Introduction
Pulmonary pressure may be increased in 
patients with heart failure (HF). Pulmonary hy-
pertension (PH) occurs in 30–35% of patients with 
HF, and carries a poor prognosis [1].
In patients referred for heart transplantation 
(HTx), PH with pulmonary vascular resistan-
ce (PVR) above 3.5 Wood Units is reported in 
20–35% [2].
According to European Society of Cardiology 
(ESC), PH is defined as a mean pulmonary artery 
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pressure higher than 25 mm Hg at rest and higher 
than 30 mm Hg with exercise [3]. Taking into 
account that mean pulmonary capillary wedge 
pressure (PCWP) in patients with severe chronic 
HF exceeds 20–22 mm Hg, one could speculate 
that PH defined in accordance with ESC criteria 
may be diagnosed in about 80% of patients.
According to International Society for Heart 
and Lung Transplantation guidelines, fixed PH 
and some other hemodynamic parameters could 
be considered a relative contraindication for HTx 
[4]. Among these are: pulmonary artery systolic 
pressure (PASP) ≥ 60 mm Hg , with PVR > 5 WU, 
or transpulmonary gradient (TPG) 16–20 mm Hg. 
The risk of right HF and early death after HTx is 
increased in this group of patients [5].
PH is a powerful predictor of mortality in HF 
and it is independent of other predictors such as: 
N-terminal of the prohormone B-type natriuretic 
peptide (NT-proBNP), echo-variables, mitral re-
gurgitation, and HF symptoms. That means that 
they should be taken into account during allocating 
(elective vs. urgent) patients for HTx [6].
Probably, the current recipient’s allocation 
system — UNOS should be modified, taking into 
account special consideration for ambulatory 
patients qualified for HTx with high risk of death 
because of PH.
Our main aim was to examine prognostic sig-
nificance of pulmonary hemodynamic variables in 
homogenic group of patients with severe chronic 
HF considered for HTx.
Methods
Study population and procedures
Between November 1 2003 and October 31 
2007 there were 658 patients with severe chronic 
HF qualified to HTx in 4 cardiac transplant centers 
in Poland. During diagnostic procedures, right he-
art catheterization was performed with the use of 
Swan-Ganz thermodilution catheter for evaluation 
of pulmonary hemodynamics. Cardiac output (CO), 
pulmonary artery pressure, PCWP, TPG, PVR and 
systemic vascular resistance (SVR) were measured 
and calculated. Among 658 patients registered, in 
559 the whole protocol of pulmonary hemodynamic 
parameter was available. During the qualification 
to HTx other standard diagnostic procedures were 
performed: biochemical evaluation (sodium, NT-
-proBNP, high sensitivity-C-reactive protein [hs-
-CRP]), 6-min walking test, maximal oxygen uptake 
(VO2max). Heart Failure Survival Score (HFSS) 
was calculated according to Aaronson.
The average observation time was 601 days 
(1–1462). Death or emergency HTx were assumed 
as the endpoints in the follow-up. Death or any kind 
of HTx were considered censoring events.
The study was approved by the local bioethical 
committee and all patients gave their informed 
consent.
Statistical analysis
The following statistical methods were used: 
means, standard deviations, medians and terciles 
in distribution. Comparisons of continuous para-
meters were conducted using analysis of variance 
(Duncan test) which met the criteria for normal 
distribution. In case of other distribution, non-pa-
rametrical Wilcoxon or Kruskal-Wallis tests were 
used. For evaluation of survival, terciles of some 
pulmonary hemodynamic variables were compared. 
Kaplan-Meier statistics were used together with 
the log-rank test for verification of the hypothesis 
of homogeneity of the survival rate curves. Pre-
diction value of the analyzed variables in terms of 
occurrence of the endpoint was analyzed using the 
Cox regression method with a single variable. Mul-
tifactor Cox regression model was built with the 
stepwise variable selection method. All analyses 
were performed using statistical package STATI-
STICA 10 and a p-value of < 0.05 was considered 
statistically significant.
Results
Between November 1 2003 and October 31 2007, 
658 patients were qualified to HTx in Poland and re-
gistered. In 559 (84.9%) full hemodynamic protocol 
was obtained. The mean follow-up was 601 days. 
Most of qualified patients (87.8%) were male. Mean 
age was 50.1 years. Most of them were in III and IV 
New York Heart Association (NYHA) class (84%).
Echo assessment of left ventricular (LV) 
function demonstrated severe heart dysfunction: 
ejection fraction 20.7%, LV end-diastolic diame-
ter 72.2 mm. Systolic blood pressure (SBP) was 
100.9 mm Hg. Median levels of standard biomar-
kers were as follows: NT-proBNP — 2.703 pg/mL, 
hs-CRP — 3.318 mg/L. An Aaronson score (HFSS) 
equal to 7.61 indicated a moderate risk of death or 
emergency HTx.
Pulmonary hemodynamic parameters mea-
sured invasively revealed PH with PASP higher 
than 35 mm Hg in 2/3 of patients. Mean PASP was 
44.3 ± 16.9 mm Hg, pulmonary gradient 10.1 ± 
± 5.6 mm Hg, and PVR 3.1 ± 2.4 Wood Unit. Mean 
value of PCWP was 21.0 ± 9.5 mm Hg.
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All patients were treated with optimally to-
lerated doses of angiotensin converting enzyme 
inhibitors and/or angiotensin II receptor blockers 
— 90% of patients (doses: ramipril 5.50 ± 4.32, 
perindopril 3.63 ± 1.63, enalapril 15.83 ± 10.88 
mg/d.). Beta-blockers — 91% of patients (doses: 
carvedilol 17.23 ± 13.64 mg/d., bisoprolol 3.59 ± 
± 2.79 mg/d.), diuretics — 93% of patients, digo-
xin — 44% of patients, mineralocorticoid receptor 
antagonists — 78% of patients by cardiologists in 
HF or transplantology departments and appropriate 
outpatient clinics.
Out of 559 patients qualified to HTx 24.9% 
died or underwent emergency HTx during the 
follow-up. Baseline characteristics of all patients 
according to PASP terciles — see Table 1.
Prognostic value of pulmonary  
hemodynamic parameters
Among 21 analyzed parameters (variables) 
age, ejection fraction [%], SBP and diastolic blood 
pressure (DBP), LV end-systolic diameter, sodium 
serum level, Aaronson risk score (HFSS), NT-
-proBNP and hs-CRP levels, PCWP, and PASP/ 
/SBP ratio, had influence on patients’ survival 
in univariate Cox regression analysis (Table 2). 
Multifactor Cox regression model revealed that 
only sodium serum level, NT-proBNP, and hs-CRP 
levels significantly influenced survival of patients 
qualified to HTx (Table 3).
The main aim of the study was to examine 
prognostic significance of pulmonary hemody-
namic variables of patients with severe chronic 
HF qualified to HTx. Among all hemodynamic 
parameters recorded during Swan-Ganz cathe-
terization SBP, PCWP, and PASP/SBP score had 
statistically significant influence on patients’ 
survival in univariate Cox regression model 
(Table 4). Some variables (SBP, PCWP, and PASP/ 
/SBP) had influence on survival or emergency 
HTx with the use of multifactor Cox regression 
model (Table 5).
For the outcome analysis Kaplan-Meier sur-
vival curves were generated and the differences 
between terciles of PCWP, PASP, SBP, and PASP/ 
/SBP score were assessed using the log-rank test.
Table 1. Baseline characteristic of all patients according to PASP terciles
PASP < 35 mm Hg* 35 mm Hg £ PASP < 50 mm Hg* PASP ≥ 50 mm Hg*
Age [years] 52.6 ± 8.6 47.9 ± 11.7 48.6 ± 11.7
Weight [kg] 78.2 ± 13.6 76.1 ± 15.0 78.8 ± 15.9
Height [cm] 172.0 ± 7.5 173.2 ± 9.4 172.8 ± 7.4
LVEF [%] 21.7 ± 7.9 19.6 ± 7.7 19.5 ± 6.6
LVEDD [mm] 72.2 ± 10.6 72.6 ± 12.5 72.7 ± 11.4 
LVESD [mm] 59.8 ± 13.7 62.9 ±12.7 62.5 ± 13.0
Heart rate [/min] 77.0 ± 14.1 79.3 ± 16.0 79.7 ± 15.3
Systolic BP [mm Hg] 102.7 ± 14.8 100.2 ± 13.5 98.7 ± 12.5
Diastolic BP [mm Hg] 66.8 ± 11.0 65.9 ± 10.8 64.5 ± 8.8
Na [mEq/L] 136.6 ± 4.3 135.9 ± 4.3 135.6 ± 4.8
VO2max 11.9 ± 3.3 12.0 ± 3.1 12.0 ± 3.0
HFSS 7.7 ± 0.9 7.6 ± 0.8 7.4 ± 0.9
NT-proBNP [pg/mL]* 1705.0 (1030.0–4130.0) 3363.0 (2055.0–5813.0) 3501.0 (1931.5–5423.5)
hs-CRP [mg/L]* 3.2 (1.1–6.3) 6.4 (0.8–8.4) 15.1 (0.1–347.0)
PASP [mm Hg] 26.6 ± 6.0 44.0 ± 4.5 63.4 ± 11.2
PCWP [mm Hg] 12.3 ± 5.5 22.2 ± 5.7 29.4 ± 7.7
TPG [mm Hg] 6.9 ± 3.6 8.8 ± 3.6 13.5 ± 6.2
Cardiac output [L/min] 4.0 ± 2.5 3.7 ± 1.2 3.6 ± 1.1
PVR [Wood Units] 2.0 ± 0.9 2.7 ± 1.5 4.1 ± 2.6
SVR [Wood Units] 22.5 ± 7.6 23.1 ± 8.4 23.4 ± 8.4
PVR/SVR 0.1 ± 0.09 0.1 ± 0.08 0.2 ± 0.08
PASP/Systolic BP 0.26 ± 0.08 0.45 ± 0.07 0.65 ± 0.14
*Mean ± standard deviation, median (low-high quartile); LVEF — left ventricular ejection fraction; LVEDD — left ventricular end-diastolic dia-
meter; LVESD — left ventricular end-systolic diameter; BP — blood pressure; Na — sodium serum concentration; HFSS — Heart Failure Sur-
vival Score; NT-proBNP — N-terminal of the prohormone B-type natriuretic peptide; hs-CRP — high sensitivity C-reactive protein;  
PASP — pulmonary artery systolic pressure; PCWP — pulmonary capillary wedge pressure; TPG — total pulmonary gradient;  
PVR — pulmonary vascular resistance; SVR — systemic vascular resistance
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There was a significant difference in survival 
between patients in whom PCWP was higher than 
25 mm Hg and those with PCWP < 25 mm Hg. No 
difference was found between those with PCWP 
16–25 mm Hg and those with PCWP 16 mm Hg 
and lower (Fig. 1).
There was a significant difference as far as 
PASP was concerned. The worst prognosis had 
the patients with PASP above 50 mm Hg — 1-, 2-, 
3-year survival was 75%, 58%, and 48%, as com-
pared to patients with PASP < 35 mm Hg (80%, 
70%, and 68%, respectively).
It is worth to note that there was no difference 
in 200 days of survival between the second and 
third tercile patients with PASP > 35 mm Hg. One 
can speculate if short-term survival is worst in pa-
tients qualified to HTx with any level of PH (Fig. 2). 
Also, systemic blood pressure had an important 
influence on survival. Patients with SBP equal or 
lower than 90 mm Hg had 1-, 2-, and 3-year survival 
66%, 53% and 48% (Fig. 3).
Because high PASP and low SBP had signi-
ficant influence on survival in cardiac transplant 
candidates we assessed prognostic value of PASP/ 
/SBP score (Fig. 4), values more than 0.52 were 
connected with worst prognosis.
Discussion
Heart transplantation is currently the best 
method of treatment for patients with terminal HF. 
Unfortunately, HTx is available only to a part of 
those qualified. Usually patients are listed for trans-
plantation only when it is presumed that they will 
live longer and function better after transplantation 
Table 2. Univariate Cox regression analyses of 
factors influencing survival of cardiac transplant 
candidates. 
Parameters HR estimates 
[univariate]
–95%CI –  
+95%CI
Age [years] 0.984* 0.968–0.999
Weight [kg] 0.997 0.985–1.009
LVEF [%] 0.948* 0.921–0.997
LVEDD [mm] 1.016 0.998–1.034
LVESD [mm] 1.018* 1.003–1.034
Heart rate [/min] 1.018* 1.008–1.029
Systolic BP [mm Hg] 0.981* 0.968–0.994
Diastolic BP [mm Hg] 0.982* 0.965–0.999
Na [mEq/L] 0.925* 0.893–0.957
HFSS 0.565* 0.468–0.687
NT-proBNP [pg/mL] 1.007* 1.005–1.009
hs-CRP [mg/L] 1.011* 1.006–1.015
PASP [mm Hg] 1.008 0.998–1.018
PCWP [mm Hg] 1.030* 1.013–1.048
TPG [mm Hg] 0.995 0.966–1.025
Cardiac output [L/min] 0.923 0.789–1.080
PVR [Wood Units] 0.990 0.927–1.058
SVR [Wood Units] 1.013 0.991–3.116
PVR/SVR 0.761 0.186–4.681
PASP/Systolic BP 11.003* 3.126–38.726
*p< 0.05; HR — hazard ratio; CI — confidence interval; rest abbre-
viations as in Table 1
Table 3. Multifactor Cox regression model built 
with stepwise variable selection method of fac-
tors influencing survival. 
Parameters HR estimates 
[multifactor]
–95%CI – 
+95%CI
hs-CRP 1.008* 1.003–1.012
Na [mEq/L] 0.927* 0.887–0.969
NT-proBNP [pg/mL] 1.006* 1.003–1.009
*p < 0.05; HR — hazard ratio; CI — confidence interval; rest abbre-
viations as in Table 1
Table 4. Univariate Cox regression analysis of 
hemodynamic parameters influencing survival.
Parameters HR estimates 
[univariate]
–95%CI – 
+95%CI
Systolic BP [mm Hg] 0.981* 0.968–0.995
Diastolic BP [mm Hg] 0.984 0.967–1.001
PASP [mm Hg] 1.008 0.998–1.018
PCWP mean [mm Hg] 1.030* 1.012–1.048
TPG [mm Hg] 0.993 0.963–1.024
Cardiac output [L/min] 0.916 0.779–1.078
PVR [Wood Units] 1.002 0.936–1.074
SVR [Wood Units] 1.014 0.992–1.036
PVR/SVR 0.842 0.106–6.669
PASP/Systolic BP 11.00* 3.126–38.726
*p < 0.05; HR — hazard ratio; CI — confidence interval; rest abbre-
viations as in Table 1
Table 5. Multifactor Cox regression model of  
arbitrary selection pulmonary hemodynamic  
parameters potentially influencing survival.
Parameters HR estimates  
[multifactor]
–95%CI –  
+95%CI
Systolic BP [mm Hg] 0.985* 0.972–0.999
PCWP mean [mm Hg] 1.025* 1.007–1.040
PASP/Systolic BP 5229.00 1.128–24.232
*p < 0.05; HR — hazard ratio; CI — confidence interval; rest abbre-
viations as in Table 1
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than on medical therapy. The main problem with 
patients listed for HTx is proper allocation. There 
is a shortage of donors leading to long waiting list, 
so organs should be allocated to the patients at 
high risk of dying, underscoring the importance 
of accurate prognosis determination.
The most widely accepted criteria for risk 
assessment are based on cardiopulmonary stress 
test (peakVO2) and HFSS. Patients with redu-
ced capacity (VO2 £ 14 mL/min/kg) had worse 
survival. HFSS this is a scoring system based 
on 7 parameters, including peak VO2, etiology of 
cardiomyopathy, resting heart rate, sodium level, 
LV ejection fraction, mean arterial blood pressure, 
and width of QRS [7]. Based on HFSS patients are 
classified into low (> 8.10), medium (7.20–8.10) 
and high-risk (< 7.19) groups. The Seattle Heart 
Failure is another widely used prognostic model, 
Figure 4. Probability of survival according to pulmonary 
artery systolic pressure vs. systolic blood pressure 
ratio; 1 tercile £ 0.36, 3 tercile > 0.52.
Figure 1. Probability of survival — patients stratified by pul-
monary capillary wedge pressure; 1 tercile £ 16 mm Hg, 
3 tercile > 25 mm Hg.
Figure 2. Probability of survival according to pulmonary 
artery systolic pressure; 1 tercile £ 35 mm Hg, 3 tercile 
> 50 mm Hg.
Figure 3. Probability of survival according to systo - 
lic blood pressure; 1 tercile £ 90 mm Hg, 3 tercile 
> 110 mm Hg.
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which takes 5 out of 7 HFSS parameters (without 
heart rate and peak VO2), along with demographic 
parameters, use of devices and some laboratory 
data [8]. Direct comparison of these two models 
shows relatively good concordance, although the 
Seattle Heart Failure Model tends to be overly op-
timistic and HFSS more pessimistic in estimating 
survival [9, 10]. 
In our study, we analyzed 21 parameters but 
only age, ejection fraction [%], SBP, DBP, LV end-
-systolic diameter, sodium serum level, HFSS and 
NT-proBNP, hs-CRP, PCWP, and PASP/SBP score 
influenced patients’ survival in univariate Cox 
regression analysis.
Pulmonary hypertension may result from an 
increase in LV filling pressure, left atrial pressure, 
and PVR. Most data underlined strong prognostic 
value of PCWP and PH [11].
Even though most of patients qualified to 
HTx have pulmonary artery hypertension, some 
authors underline neutral influence of PH on their 
prognosis [12, 13]. A possible explanation for this 
observation is that patients on the waiting list to 
HTx are highly selected, homogenous with termi-
nal HF, thus limiting the chances for identifying dif-
ferences. Finally, some patients with fixed PH are 
disqualified from HTx. Usually PH can cause right 
ventricular (RV) dysfunction. PH and RV dysfun-
ction carry a poor prognosis and increase the risk of 
postoperative RV failure after HTx [14]. Tricuspid 
regurgitation is often a consequence of PH. RV dys-
function is usually associated with reduced CO and 
pulmonary blood flow, so hemodynamic parameters 
of pulmonary circulation, especially prognostic 
value of PASP may be underestimated in these 
circumstances. Nevertheless, PASP exceeding 
45 mm Hg is associated with worse prognosis. Our 
results are in accordance with these observations.
Among 9 hemodynamic parameters analyzed 
only SBP, PCWP, and PASP/SBP score statistical-
ly influenced survival using univariate as well as 
multivariate Cox regression models.
Using Kaplan-Maier long rang test we com-
pared probability of survival patients stratified 
by terciles. Pulmonary capillary wedge pres-
sure above 25 mm Hg was connected with sig-
nificantly worse prognosis. One-year survival 
was 65%, 3-year — 40%. Patients with PCWP 
< 25 mm Hg had 1-year and 3-year survival (80% 
and 50%, respectively). Pulmonary pressure has 
also significant influence on survival. Patients with 
PASP above 50 mm Hg had worse prognosis com-
pared to patients with PASP < 35 mm Hg. An inte-
resting finding is that PASP exceeding 35 mm Hg 
had negative influence on survival during first 
200 days of observation as compared to patients 
with PASP < 35 mm Hg.
Score PASP/SBB higher than 0.52 had signi-
ficant influence on survival in cardiac transplant 
candidates.
Conclusions
In patients with acute chronic HF qualified 
to HTx, pathological values of pulmonary hemo-
dynamic parameters have a significant influence 
on survival. Any kind of pulmonary artery hy-
pertension may influence short-term prognosis. 
Pulmonary hemodynamic parameters should be 
taken into account during allocation of ambulatory 
candidates for HTx.
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